ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia

This publication has 103 references indexed in Scilit:

• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
  The Lancet, 2015
• Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
  New England Journal of Medicine, 2014
• Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002
  British Journal of Haematology, 2014
• Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia
  Journal of Clinical Oncology, 2012
• Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
  Journal of Clinical Oncology, 2011
• Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
  Journal of Clinical Oncology, 2010
• Modulation of antigen expression in B‐cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug‐induced regulatory phenomenon. Results of the AIEOP‐BFM‐ALL‐FLOW‐MRD‐Study Group
  Cytometry Part B: Clinical Cytometry, 2010
• Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
  Science, 2008
• Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia
  Cancer, 2006
• Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients
  Clinical Infectious Diseases, 2001